Fomivirsen

Summary

Fomivirsen (CHEMBL1201688) is an approved oligonucleotide (ATC S01AD08); indicated across 3 conditions including eye infectious disorder and hiv infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Oligonucleotide
• ATC class: S01AD08
• Indications: 3 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201688
Name	Fomivirsen
Type	Oligonucleotide
Max phase	4
ATC	S01AD08

Also known as: Fomivirsen, Vitravene, FOMIVIRSEN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
eye infectious disorder	4	MONDO:0043885	EFO:1001888
HIV infectious disease	4	MONDO:0005109	EFO:0000764
cytomegalovirus retinitis	4	MONDO:0000878	EFO:1001302

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).